Afatinib with concurrent radiotherapy in a patient with metastatic non-small cell lung cancer.


BACKGROUND The combination of radiotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) has not been widely investigated. For afatinib, a new second generation irreversible pan-EGFR TKI, no clinical trials in this… (More)
DOI: 10.1159/000362488


1 Figure or Table

Slides referencing similar topics